CLINICAL_TRIALS
trial_result
· 2020-12-17
Clinical Trial Update: Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma [Phase 2]
Summary
Phase 2 trial evaluating BHQ880 in patients with high-risk smoldering multiple myeloma has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Smoldering Multiple Myeloma | Phase 2 | Status: COMPLETED